Research graph
References from The safety and efficacy of different anti-tuberculosis regimens containing Lzd for RR/MDR/Pre-XDR-TB patients in China. Local targets link to admitted publications; unresolved targets remain external evidence.
Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis.
10.1371/journal.pone.0270003 · 2022 · External reference
Prevalence of multidrug-resistant tuberculosis in East Africa: a systematic review and meta-analysis.
10.1371/journal.pone.0270272 · 2022 · External reference
Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis.
10.1016/j.jinf.2018.10.004 · 2018 · External reference
Risk factors of multidrug-resistant tuberculosis in China: a meta-analysis.
10.1111/phn.12582 · 2019 · External reference
An overview of new antitubercular drugs, drug candidates, and their targets.
10.1002/med.21602 · 2020 · External reference
Linezolid: a promising agent for the treatment of multiple and extensively drug-resistant tuberculosis.
10.3897/folmed.62.e48742 · 2020 · External reference
Effect of linezolid plus bedaquiline against mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay.
10.1128/aac.00856-18 · 2018 · External reference
Repurposing immunomodulatory drugs to combat tuberculosis.
10.3389/fimmu.2021.645485 · 2021 · External reference
Population pharmacokinetics and bayesian dose adjustment to advance TDM of Anti-TB drugs.
10.1007/s40262-021-00997-0 · 2021 · External reference
Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.
10.1186/s12941-016-0156-y · 2016 · External reference
Tuberculous meningitis: progress and remaining questions.
10.1016/s1474-4422(21)00435-x · 2022 · External reference
The efficacy and safety of bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and meta-analysis.
10.3390/antibiotics12091389 · 2023 · External reference
Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
10.36416/1806-3756/e20210384 · 2022 · External reference
Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
10.1186/s12879-022-07693-9 · 2022 · External reference
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
10.1016/s0140-6736(18)31644-1 · 2018 · External reference
New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians.
10.1159/000528274 · 2023 · External reference
Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.
10.1371/journal.pgph.0000818 · 2023 · External reference
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
10.1016/s2213-2600(18)30426-0 · 2019 · External reference
Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective.
10.2217/fmb-2019-0309 · 2020 · External reference
Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
10.1016/j.ijid.2023.04.392 · 2023 · External reference
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
10.1186/s12879-021-06024-8 · 2021 · External reference
Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline- or delamanid-containing regimens.
10.1093/cid/ciz1107 · 2020 · External reference
Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis.
10.1093/cid/ciac876 · 2023 · External reference
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.
10.3389/fcimb.2023.1183597 · 2023 · External reference
The struggle to end a millennia-long pandemic: novel candidate and repurposed drugs for the treatment of tuberculosis.
10.1007/s40265-022-01817-w · 2022 · External reference
Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment.
10.1093/cid/ciy625 · 2018 · External reference
Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.
10.1128/aac.01381-21 · 2021 · External reference
Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
10.1186/s40249-021-00819-2 · 2021 · External reference
Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
10.1016/j.ijid.2022.02.043 · 2022 · External reference
An overview of new antitubercular drugs, drug candidates, and their targets.
10.1002/med.21602 · ExternalCitation · doi-reference
Population pharmacokinetics and bayesian dose adjustment to advance TDM of Anti-TB drugs.
10.1007/s40262-021-00997-0 · ExternalCitation · doi-reference
The struggle to end a millennia-long pandemic: novel candidate and repurposed drugs for the treatment of tuberculosis.
10.1007/s40265-022-01817-w · ExternalCitation · doi-reference
Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
10.1016/j.ijid.2022.02.043 · ExternalCitation · doi-reference
Epidemiology of extensively drug-resistant tuberculosis among patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis.
10.1016/j.ijid.2023.04.392 · ExternalCitation · doi-reference
Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis.
10.1016/j.jinf.2018.10.004 · ExternalCitation · doi-reference
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
10.1016/s0140-6736(18)31644-1 · ExternalCitation · doi-reference
Tuberculous meningitis: progress and remaining questions.
10.1016/s1474-4422(21)00435-x · ExternalCitation · doi-reference
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
10.1016/s2213-2600(18)30426-0 · ExternalCitation · doi-reference
Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis.
10.1093/cid/ciac876 · ExternalCitation · doi-reference
Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB treatment.
10.1093/cid/ciy625 · ExternalCitation · doi-reference
Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline- or delamanid-containing regimens.
10.1093/cid/ciz1107 · ExternalCitation · doi-reference
Risk factors of multidrug-resistant tuberculosis in China: a meta-analysis.
10.1111/phn.12582 · ExternalCitation · doi-reference
Effect of linezolid plus bedaquiline against mycobacterium tuberculosis in log phase, acid phase, and nonreplicating-persister phase in an in vitro assay.
10.1128/aac.00856-18 · ExternalCitation · doi-reference
Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.
10.1128/aac.01381-21 · ExternalCitation · doi-reference
New and repurposed drugs for the treatment of active tuberculosis: an update for clinicians.
10.1159/000528274 · ExternalCitation · doi-reference
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China.
10.1186/s12879-021-06024-8 · ExternalCitation · doi-reference
Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
10.1186/s12879-022-07693-9 · ExternalCitation · doi-reference
Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.
10.1186/s12941-016-0156-y · ExternalCitation · doi-reference
Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
10.1186/s40249-021-00819-2 · ExternalCitation · doi-reference
Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.
10.1371/journal.pgph.0000818 · ExternalCitation · doi-reference
Risk factors for multidrug-resistant tuberculosis: a worldwide systematic review and meta-analysis.
10.1371/journal.pone.0270003 · ExternalCitation · doi-reference
Prevalence of multidrug-resistant tuberculosis in East Africa: a systematic review and meta-analysis.
10.1371/journal.pone.0270272 · ExternalCitation · doi-reference
Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective.
10.2217/fmb-2019-0309 · ExternalCitation · doi-reference
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.
10.3389/fcimb.2023.1183597 · ExternalCitation · doi-reference
Repurposing immunomodulatory drugs to combat tuberculosis.
10.3389/fimmu.2021.645485 · ExternalCitation · doi-reference
The efficacy and safety of bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and meta-analysis.
10.3390/antibiotics12091389 · ExternalCitation · doi-reference
Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
10.36416/1806-3756/e20210384 · ExternalCitation · doi-reference
Linezolid: a promising agent for the treatment of multiple and extensively drug-resistant tuberculosis.
10.3897/folmed.62.e48742 · ExternalCitation · doi-reference
